ProstaLund AB - Interim report January-June 2024
ProstaLund is on a good track to establish CoreTherm® internationally again
Second quarter
April 1 - June 30
- Net sales reached SEK 2,8 (5,3) million
- Operating profit/loss totaled SEK -7,2 million (-4,0) million
- Loss after taxes SEK -7,2 (-4,1) million
- Earnings per share, SEK (basic and diluted) amounted to SEK -0,09 (-0,07)
- Cash flow from operating activities amounted to SEK -6,6 (-0,5) million
January 1 - June 30
- Net sales reached SEK 6,3 (10,9) million
- Operating profit/loss totaled SEK -11,9 million (-7,2) million
- Loss after taxes SEK -12,0 (-7,3) million
- Earnings per share, SEK (basic and diluted) amounted to SEK -0,16 (-0,12)
- Cash flow from operating activities amounted to SEK -12,7 (-6,0) million
- Cash and cash equivalents amounted to SEK 3,4 (34,1) million as per June 30, 2024
Significant events during the period
- Two new studies with ProstaLund’s Schelin Catheter® presented at the EAU in Paris on April 8
- Positive results from unannounced inspection by TÜV SÜD, regarding our regulatory authorisations conducted on April 9-10
- ProstaLund and Capio Specialistcenter AB signed on Aprill 22 a new agre- ement regarding disposable materials used in CoreTherm® treatments. The agreement is over 12 months, with an option to extend. The order value is approximately SEK 1,3 million over the contract period. The agreement repla- ces the previous agreement with Capio Specialistcenter AB
- ProstaLund decided on May 20 that the Board of Directors intends to decide on a rights issue of units for an initial issue amount of around 29 MSEK
- The preliminary investigation towards the former Chairman and major share- holders of the Company was closed on May 23
- ProstaLund received a certificate with MDR and ISO13485 from TÜV SÜD on May 27
- The communique from the annual general meeting was published on May 30
- New agreement signed on May 31st regarding CoreTherm® treatments in Austria
- Bridge loan amounting to 4 MSEK was signed with the main owner on June 10
- New agreement signed on June 24 regarding CoreTherm® treatments in Arhus, Denmark
- The outcome of the rights issue was published on June 28. Around 80 per- cent or SEK 23 million was reached before deduction of the costs related to the transaction
Significant events after the end of the period
- ProstaLund informed on July 3rd that a direct issue of units instead of cash compensation to one Guarantor will be performed in connection with the right issue
- ProstaLund informed on July 11 that it will announce the last day of trading in BTUs after the rights issue has been registered.
- ProstaLund informed on July 17 the last day of trading in BTUs and the first day of trading in warrants of series TO 3.
Key figures
(SEK MILLION) | APRIL-JUNE 2024 | APRIL-JUNE 2023 | JAN-JUNE 2024 | JAN-JUNE 2023 |
Net sales | 2,8 | 5,3 | 6,3 | 10,9 |
Gross Margin, (%) | 74,1 | 67,5 | 71,7 | 67,9 |
Operating profit/loss, EBIT | -7,2 | -4,0 | -11,9 | -7,2 |
Cash flow from operating activites | -6,1 | -0,5 | -12,7 | -6,0 |
Cash and cash equivalents | 3,4 | 34,1 | 3,4 | 34,1 |
Average number of employees | 8 | 9 | 6 | 9 |
”With a new organisation in place, we are moving full speed ahead!”
Anders Kristensson
CEO, ProstaLund AB (publ)
Please see attached PDF for full report.